TLDRs;

Merck stock rose 2.2% in after-hours trading following a volatile day on the NYSE.

The company’s 2026 revenue forecast came in below Wall Street expectations, raising concerns about patent expirations and competition.

Investors are closely tracking the performance and demand of Keytruda and Gardasil amid shifting market conditions.

The upcoming FDA Winrevair label update and other regulatory decisions are expected to influence Merck’s stock performance this year

Merck & Co (NYSE:MRK) saw its shares rise roughly 2.2% in after-hours trading Tuesday, ending the session at $115.84. Earlier in the day, the stock had experienced a volatile range, swinging between $109.02 and $118.35. Analysts say the after-hours gain reflects investor focus on the company’s strategic positioning for 2026, even as its revenue forecast fell short of Wall Street expectations.

The pharmaceutical giant is entering the year with a familiar tension: its oncology drugs, particularly Keytruda, continue to show strong growth, while aging medications face patent expirations. This dynamic, often referred to in the industry as “loss of exclusivity,” has prompted investors to weigh near-term revenue pressures against long-term pipeline potential.

Revenue Forecast Misses Wall Street Estimates

Merck projected full-year 2026 revenue between $65.5 billion and $67.0 billion, below the $67.6 billion analyst consensus at the upper range. The company cited several headwinds, including approximately $2.5 billion in expected losses from generic competition, ongoing Medicare pricing discussions, and softer sales of its COVID-19 treatment, Lagevrio.

Merck & Co., Inc., MRK

Despite the revenue shortfall, the company posted a 5% increase in fourth-quarter global sales, reaching $16.4 billion. Non-GAAP earnings were $2.04 per share, excluding certain items.

Merck also provided 2026 non-GAAP earnings guidance of $5.00 to $5.15 per share, which factors in a one-time $3.65 per share charge related to its acquisition of Cidara Therapeutics. CEO Robert M. Davis emphasized that the company’s “momentum is building as we continue to execute on our strategy.”

Investors Eye Keytruda and Gardasil Trends

Market attention is concentrated on Merck’s flagship products. Keytruda remains a cornerstone of the oncology portfolio, but questions linger about how well the company can offset losses from off-patent medications.

Meanwhile, Gardasil has faced setbacks in the Chinese market, further intensifying scrutiny of Merck’s revenue streams. Analysts caution that unexpected drops in demand or tougher-than-anticipated pricing pressures in the U.S. could challenge the company’s “bridge year” narrative for 2026.

FDA Milestones Will Drive Stock Direction

Merck has outlined a series of upcoming FDA milestones that investors are closely monitoring. The most notable is the PDUFA date for Winrevair, set for September 21, 2026, which will determine approval for a label update. Additional regulatory decisions are expected throughout the second half of the year, providing potential catalysts for stock movement.

As trading resumes during the regular U.S. session, the after-hours gains will be tested against broader market activity. Analysts note that Merck has a history of sharp stock swings in response to even minor shifts in outlook, emphasizing the importance of 2026 as a pivotal year. Investors will be closely tracking both product demand and FDA progress as the company navigates patent expirations, generic competition, and ongoing strategic initiatives.

The post Merck (MRK) Stock; Up After Volatile Session Despite Revenue Forecast Miss appeared first on CoinCentral.

---

Filed under: News - @ March 5, 2026 9:23 am